Formulation Solutions for Diversifying Biopharmaceutical Portfolios

The structural complexity of traditional biopharmaceuticals, such as monoclonal antibodies, means that the formulation development of the ever-increasing and diversifying portfolio of such molecules remains challenging and requires continued innovation to accelerate development timelines. In recent years the development of next generation biomedicines (cell and gene therapies, antibody drug conjugates and nucleic acid therapeutics) challenges the embedded methods of formulation development, designed around optimisation of protein therapeutics. This meeting will present on the fundamentals and application of formulation development for existing and emerging biomedicines. Free to attend